Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
| Chemical Name |
6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone |
| Synonyms |
6-(p-Aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone; 1,4-Dihydro-4-Methyl-3-(4-Aminophenyl)pyridazine-6(5H)-one ; Levosimendan Impurity 5 |
| CAS Number |
36725-28-7 |
| CAT Number |
RF-PI1976 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C11H13N3O |
| Molecular Weight |
203.25 |
| Melting Point |
194.0 to 198.0℃ |
| Density |
1.30±0.10 g/cm3 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Off-White to Pale Brownish Color Powder |
| Identification (HPLC) |
HPLC RT of the major peak corresponds to that of the in-house working standard |
| Loss on Drying |
<0.50% |
| Residue on Ignition |
<0.20% |
| Related Substances |
(HPLC) |
| Single Impurity |
<0.20% |
| Total Impurities |
<0.50% |
| Purity / Analysis Method |
>99.5% (HPLC) |
| Heavy Metals |
<20ppm |
| Proton NMR Spectrum |
Conforms to Structure |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Levosimendan (CAS: 141505-33-1)
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) is an intermediate of Levosimendan (CAS: 141505-33-1). Levosimendan was introduced in Sweden as an i.v. infusion for the treatment of acute heart failure or refractory symptoms of chronic heart failure in cases where conventional treatment (e.g., diuretic or ACE inhibitor) is not sufficient. It also activates ventricular and arterial adenostne triphosphate-regulated potassium channels which causes vasodilatation in vascular smooth muscle and protects myocardium against infarction. Its low phosphodiesterase III inhibiting activity is probably not responsible for its positive inotropic, lusitropic and dilating effects. Unlike other cardiotonic drugs, levosimendan is able to produce positive inotropic effects without prolonging myocardial relaxation or increasing the incidence of malignant arrythmias. It was clinically shown to have a lower risk of mortality in patients with heart failure when compared to placebo and dobutamine. Since it has a larger potential, levosimendan is currently under further clinical evaluation as a chronic treatment for congestive heart failure.